WO1999058557A3 - Dimers of the hla-b27 heavy chain extracellular domain and uses thereof - Google Patents

Dimers of the hla-b27 heavy chain extracellular domain and uses thereof Download PDF

Info

Publication number
WO1999058557A3
WO1999058557A3 PCT/GB1999/001481 GB9901481W WO9958557A3 WO 1999058557 A3 WO1999058557 A3 WO 1999058557A3 GB 9901481 W GB9901481 W GB 9901481W WO 9958557 A3 WO9958557 A3 WO 9958557A3
Authority
WO
WIPO (PCT)
Prior art keywords
hla
heavy chain
extracellular domain
dimer
dimers
Prior art date
Application number
PCT/GB1999/001481
Other languages
French (fr)
Other versions
WO1999058557A2 (en
Inventor
Rachel Louise Allen
Paul Bowness
Andrew James Mcmichael
Original Assignee
Isis Innovation
Rachel Louise Allen
Paul Bowness
Andrew James Mcmichael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, Rachel Louise Allen, Paul Bowness, Andrew James Mcmichael filed Critical Isis Innovation
Priority to EP99921016A priority Critical patent/EP1078055A2/en
Priority to AU38390/99A priority patent/AU759065B2/en
Priority to CA002331455A priority patent/CA2331455A1/en
Publication of WO1999058557A2 publication Critical patent/WO1999058557A2/en
Publication of WO1999058557A3 publication Critical patent/WO1999058557A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A substantially isolated dimer comprising first and second cross-linked polypeptides, wherein said polypeptides comprise the extracellular domain portions of the HLA-B27 heavy chain and are capable of binding a HLA-B27 epitope, or a substantially isolated functional dimeric or multimeric analogue thereof which is capable of binding said HLA-B27 epitope and/or competes for binding to a specific receptor for said dimer. The dimer can be used to determine the onset of, or predisposition to a spondyloarthropathy. The dimer can also be used as a treatment or prophylactic for a spondyloarthropathy.
PCT/GB1999/001481 1998-05-11 1999-05-11 Dimers of the hla-b27 heavy chain extracellular domain and uses thereof WO1999058557A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99921016A EP1078055A2 (en) 1998-05-11 1999-05-11 Dimers of the hla-b27 heavy chain extracellular domain and uses thereof
AU38390/99A AU759065B2 (en) 1998-05-11 1999-05-11 Novel molecule and diagnosis method
CA002331455A CA2331455A1 (en) 1998-05-11 1999-05-11 Novel molecule and diagnosis method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9810099.3 1998-05-11
GBGB9810099.3A GB9810099D0 (en) 1998-05-11 1998-05-11 Novel molecule and diagnostic method

Publications (2)

Publication Number Publication Date
WO1999058557A2 WO1999058557A2 (en) 1999-11-18
WO1999058557A3 true WO1999058557A3 (en) 2000-02-10

Family

ID=10831867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001481 WO1999058557A2 (en) 1998-05-11 1999-05-11 Dimers of the hla-b27 heavy chain extracellular domain and uses thereof

Country Status (5)

Country Link
EP (1) EP1078055A2 (en)
AU (1) AU759065B2 (en)
CA (1) CA2331455A1 (en)
GB (1) GB9810099D0 (en)
WO (1) WO1999058557A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
WO2009090651A2 (en) * 2008-01-15 2009-07-23 Technion Research And Development Foundation Ltd. Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
EP3333186B9 (en) 2012-03-28 2023-10-04 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
WO2016124661A1 (en) 2015-02-04 2016-08-11 Universität Zürich Use of hla-b27 homodimers for cancer treatment
WO2017153438A1 (en) * 2016-03-08 2017-09-14 Universität Zürich Hla-b57 open conformers
CA3027124A1 (en) 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
CN109562171B (en) 2016-08-10 2023-10-17 苏黎世大学 MHC class Ia open conformational isomers
AU2022322029A1 (en) * 2021-08-05 2024-02-15 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007070A1 (en) * 1990-10-23 1992-04-30 Board Of Regents, The University Of Texas System Transgenic rats and animal models of inflammatory disease
WO1997000084A1 (en) * 1995-06-16 1997-01-03 President And Fellows Of Harvard College Nonimmunogenic mhc-blocking peptides
WO1998012221A1 (en) * 1996-09-18 1998-03-26 Gerhild Wildner Peptide as diagnostic and therapeutic agent for autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007070A1 (en) * 1990-10-23 1992-04-30 Board Of Regents, The University Of Texas System Transgenic rats and animal models of inflammatory disease
WO1997000084A1 (en) * 1995-06-16 1997-01-03 President And Fellows Of Harvard College Nonimmunogenic mhc-blocking peptides
WO1998012221A1 (en) * 1996-09-18 1998-03-26 Gerhild Wildner Peptide as diagnostic and therapeutic agent for autoimmune diseases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALLEN R ET AL: "Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure", J. IMMUNOL., vol. 162, no. 9, 1 May 1999 (1999-05-01), pages 5045 - 5048, XP002123588 *
ALLEN R ET AL: "Expression and folding of HLA B27 in vitro", BRITISH JOURNAL OF RHEUMATOLOGY, vol. 37, no. Supp. 1, 1998, pages 41 - Abstract 72, XP000856205 *
CAPPS G ET AL: "In vivo dimeric association of class I MHC heavy chains. Possible relationship to class I MHC heavy chain-beta 2-microglobulin dissociation", J IMMUNOL, vol. 151, no. 1, 1 July 1993 (1993-07-01), pages 159 - 169, XP002123589 *
CRESSWELL P ET AL: "Dimeric and monomeric forms of HL-A antigens solubilized by detergent", J. IMMUNOL., vol. 114, January 1975 (1975-01-01), pages 523 - 525, XP002123805 *
CUVELIER C ET AL: "Expression of T cell receptors alpha beta and gamma delta in the ileal mucosa of patients with Crohn's disease and with spondylarthropathy", CLIN EXP IMMUNOL, vol. 90, no. 2, November 1992 (1992-11-01), pages 275 - 279, XP002123806 *
RAGHAVAN M ET AL: "Extended repertoire of permissible peptide ligands for HLA-B2702", PROTEIN SCI, vol. 5, no. 10, 5 October 1996 (1996-10-05), pages 2080 - 2088, XP002123591 *
WHELAN M ET AL: "Chemical reactivity of an HLA-B27 thiol group", EUR J IMMUNOL, vol. 23, no. 12, December 1993 (1993-12-01), pages 3278 - 3285, XP002123590 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease

Also Published As

Publication number Publication date
AU759065B2 (en) 2003-04-03
CA2331455A1 (en) 1999-11-18
AU3839099A (en) 1999-11-29
EP1078055A2 (en) 2001-02-28
GB9810099D0 (en) 1998-07-08
WO1999058557A2 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
WO1999058557A3 (en) Dimers of the hla-b27 heavy chain extracellular domain and uses thereof
AU4622297A (en) Monoclonal antibodies against the extracellular domain of human vegf-receptor protein (kdr)
DK0916266T3 (en) Topping for drinks
WO2001016114A3 (en) Heterocyclic compounds and methods for modulating cxcr3 function
PL328947A1 (en) Isolated dimetric protein capable to activate the alpha fibroblasts and application thereof
AU6000098A (en) Hydrogenation of hydrocarbons
EP1231218A3 (en) An appetite-suppressing peptide, its compositions and use
AU1652197A (en) Novel estrogen receptor
AU8909798A (en) Catalytic distillation and hydrogenation of heavy unsaturates in an olefins plant
AU4783496A (en) Covering for a table top
AU3528897A (en) Catalyst composition useful for hydrogenating unsaturated hydrocarbons
AU1685597A (en) Improved olefin addition polymerization catalyst composition
AU3678897A (en) Adhesion promoters for anionic bituminous emulsions
ZA977601B (en) Adhesion enhancers for anionic bituminous emulsions.
ZA983628B (en) Process for the conversion of hzdrocarbons to olefins and aromatics
FR2704753B1 (en) USE OF DERIVATIVES OF 4-THIO RESORCIN OR 4-THIO 1-3-DIHYDROXYBENZENE, IN COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS WITH DEPIGMENTING ACTION.
WO2007000675A3 (en) Recombinant trimeric 4-1bbl
WO2001012658A3 (en) Human icos ligand and application thereof
WO2001042284A3 (en) Protein comprising ig-like domain 4 of a vegf receptor mediates receptor dimerization, but not activation
DE29606556U1 (en) Cover for drinking vessels or the like.
DE29601203U1 (en) Tray, in particular serving tray
WO2001012664A3 (en) Notch receptor ligands and uses thereof
PL333507A1 (en) Cross-propagated dimerisation of olefins
EP1012313A4 (en) INTRACELLULAR INHIBITORS OF Gq PROTEIN SIGNALING
EP1908835A3 (en) Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2331455

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 38390/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999921016

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09700158

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999921016

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 38390/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999921016

Country of ref document: EP